Masakazu Hatano
Overview
Explore the profile of Masakazu Hatano including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
216
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kishi T, Citrome L, Sakuma K, Hamanaka S, Nishii Y, Hatano M, et al.
Pharmacopsychiatry
. 2025 Jan;
PMID: 39880004
The United States Food and Drug Administration approved the xanomeline-trospium combination in September 2024 for treating schizophrenia, based in part on three double-blind, randomized placebo-controlled trials in adults with schizophrenia...
2.
Kishi T, Sakuma K, Hatano M, Iwata N
Brain Stimul
. 2025 Jan;
18(1):176-178.
PMID: 39824454
No abstract available.
3.
Kishi T, Matsuda Y, Hatano M, Sakuma K, Iwata N
J Affect Disord
. 2025 Jan;
374:616-618.
PMID: 39824318
No abstract available.
4.
Sogawa R, Hatano M, Nishimura F, Nishi J, Matsuoka A, Shinada K, et al.
In Vivo
. 2024 Dec;
39(1):433-439.
PMID: 39740920
Background/aim: The use of hypnotic drugs can lead to accidents and injuries. However, few reports have shown their association with these events after adjusting for many concomitant medications. This study...
5.
Utsunomiya A, Koseki T, Hatano M, Kondo M, Imaizumi K, Yamada S
Expert Opin Drug Saf
. 2024 Dec;
:1-8.
PMID: 39688503
Background: Immune checkpoint inhibitors (ICIs) play a central role in cancer immunotherapy. However, the occurrence of immune-related adverse events, especially ICI-induced interstitial lung disease (ICI-ILD), is life-threatening and affects the...
6.
Kishi T, Ikuta T, Sakuma K, Hamanaka S, Nishii Y, Hatano M, et al.
JAMA Netw Open
. 2024 Oct;
7(10):e2441159.
PMID: 39446321
Importance: To date, several theta burst stimulation (TBS) protocols, such as intermittent TBS (iTBS), have been proposed; however, previous systematic reviews have revealed inconsistent efficacy findings in individual TBS studies...
7.
Hatano M, Araki H, Saito T, Yamada S
Clin Psychopharmacol Neurosci
. 2024 Jul;
22(3):442-450.
PMID: 39069683
Objective: This pharmacovigilance study evaluated the profile of clozapine-related adverse events by region using the Food and Drug Administration Adverse Event Reporting System (FAERS). Methods: We categorized each case into...
8.
Hatano M, Sogawa R, Shin K, Esumi S, Ishikawa A, Mizumura R, et al.
Gen Hosp Psychiatry
. 2024 Jun;
90:50-55.
PMID: 38941744
Objective: Several medications are associated with delirium; however, studies with adequate statistical power are limited, and it is difficult to determine the effects of the various concomitant medications used in...
9.
Kishi T, Ikuta T, Sakuma K, Hatano M, Matsuda Y, Wilkening J, et al.
Mol Psychiatry
. 2024 Jun;
29(12):3893-3899.
PMID: 38844532
In clinical practice, theta burst stimulation (TBS) presents as a more efficient and potentially more effective therapeutic modality than conventional repetitive transcranial magnetic stimulation (rTMS), as it allows for the...
10.
Kishi T, Sakuma K, Hatano M, Okumura T, Kato M, Baba H, et al.
Neuropsychopharmacol Rep
. 2024 Feb;
44(1):267-271.
PMID: 38318955
Aim: To update the major depressive disorder (MDD) treatment guidelines of the Japanese Society of Mood Disorders, we conducted a systematic review and pairwise meta-analysis of double-blind, randomized, placebo-controlled trials...